Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study
- 7 March 2009
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 49 (3) , 291-300
Abstract
This was a randomized, 4‐way crossover, third‐party‐blinded study in 68 healthy subjects to assess the effect of nelfinavir on QTc interval. Treatments included (A) nelfinavir 1250 mg every 12 hours on days 1–4, (B) nelfinavir 1250 mg every 12 hours on days 1–3 plus 3125 mg on day 4, (C) placebo, and (D) moxifloxacin 400 mg every 24 hours on days 1–4. Pharmacokinetics and triplicate 12‐lead electrocardiograms were performed over 12 hours on days 1 and 4. Time‐matched, placebo‐subtracted, baseline‐adjusted changes in QT intervals with Fridericia's (QTcF) correction were determined following nelfinavir and moxifloxacin administration. Neither dose of nelfinavir had a clinically relevant effect on the QTcF interval on day 4 (primary endpoint) and day 1 because at every time point the upper 90% confidence limit was below 10 milliseconds and, furthermore, the mean difference was below 5 milliseconds. Additionally, there was no clinically relevant effect on QTcB (Bazett's correction), uncorrected QT, or the RR interval on days 1 or 4. Pharmacokinetics confirmed adequate systemic exposure to nelfinavir and moxifloxacin. While nelfinavir exposure was higher in poor compared with extensive metabolizers of CYP2C19 isozyme, there were no corresponding significant differences in QTcF change from placebo. At clinically relevant, doses nelfinavir is unlikely to cause QTc prolongation.Keywords
This publication has 13 references indexed in Scilit:
- Significant Decrease in Nelfinavir Systemic Exposure After Omeprazole Coadministration in Healthy SubjectsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Ritonavir 100 mg Does Not Cause QTc Prolongation in Healthy Subjects: A Possible Role as CYP3A Inhibitor in Thorough QTc StudiesClinical Pharmacology & Therapeutics, 2007
- Prolonged QT Interval and Torsades de Pointes Associated with Atazanavir TherapyClinical Infectious Diseases, 2007
- A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV‐positive patientsHIV Medicine, 2006
- Global QT measurements in the Philips 12-lead algorithmJournal of Electrocardiology, 2005
- Blockade of HERG channels by HIV protease inhibitorsThe Lancet, 2005
- NelfinavirDrugs, 2005
- CONVERSION OF THE HIV PROTEASE INHIBITOR NELFINAVIR TO A BIOACTIVE METABOLITE BY HUMAN LIVER CYP2C19Drug Metabolism and Disposition, 2004
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002
- Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral ActivitiesAntimicrobial Agents and Chemotherapy, 2001